Trials / Completed
CompletedNCT00500305
The Use of B-type Natriuretic Peptide (BNP) to Predict Closure of a Patent Ductus Arteriosus (PDA) in Premature Infants
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 60 (actual)
- Sponsor
- University of Virginia · Academic / Other
- Sex
- All
- Age
- 4 Months
- Healthy volunteers
- Not accepted
Summary
A patent ductus arteriosus (PDA) is associated with increased morbidity in premature infants. Standard indomethacin treatment is associated with intestinal and renal morbidity. B-type natriuretic peptide is elevated in significant PDAs. This study will determine whether BNP guided therapy could reduce doses of indomethacin.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| PROCEDURE | Withhold standard INDO dose if BNP < 100 pg/ml |
Timeline
- Start date
- 2004-04-01
- Completion
- 2007-03-01
- First posted
- 2007-07-12
- Last updated
- 2018-05-07
Source: ClinicalTrials.gov record NCT00500305. Inclusion in this directory is not an endorsement.